1. Kim SH, Fechner J. Remimazolam ‒ current knowledge on a new benzodiazepine intravenous anesthetic agent. Korean J Anesthesiol. 2022;74:307−15.

2. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115:274−83.

3. Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118:85−113.

4. Stöhr T, Colin PJ, Ossig J, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127:415−23.

5. Sheng XY, Liang Y, Yang XY, et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol. 2020;76:383−91.

6. BYFAVO (remimazolam) for injection, for intravenous use 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf.

7. Sasaki H, Hoshijima H, Mizuta K. Ringer's acetate solution induced precipitation of remimazolam. Br J Anaesth. 2021;126: e87−e9.

8. Yoshida K, Tanaka S, Watanabe K. A case of intravenous line occlusion when using Acetated Ringer's solution and remimazolam. J Clin Anesth. 2021;70:110190.

9. Weinberg L, Collins N, Van Mourik K, Tan C, Bellomo R. Plasma-Lyte 148: A clinical review. Eur J Clin Pharmacol. 2016;5:235−50.